19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace





powered by centersite dot net
Women's Health
Basic InformationLatest News
Exercise Might Make Breast Milk's Goodness Even BetterPreterm Birth Ups Mom's Long-Term Heart Disease Risk: StudyAffection, at Least for Women, May Be Rooted in GenesHormones May Explain Greater Prevalence of Alzheimer's in WomenCoronavirus Delivering a Big Economic Blow to WomenAHA News: Persistent Depression Might Increase Heart Disease Risk for Women With HIVStatins Tied to Significantly Lower Death Rate From Ovarian CancerPandemic Affecting Mental Health of Pregnant Women, New MomsClimate Change, Smog Could Mean More Preemie Babies: StudyFemale Athletes Shortchange Themselves on NutritionWomen Still Left Out of Much Medical ResearchAHA News: Pregnant Women With Heart Defects Don't Always Get This Recommended TestNot a Myth -- Contraceptives Can Cause Weight GainMeds Like Valium, Xanax Linked to Higher Risk of Ectopic PregnancyAt-Home Gene Test for Breast, Ovarian Cancers Looks EffectivePlacenta's Hidden Mysteries Revealed in MRI StudyLost Pregnancies, Diabetes May Be LinkedWomen Less Likely to Get Standard Heart MedicationsGood News for Menopausal Women Who Take HopsBlack and White Women Share the Same Genetic Risk for Breast Cancer'Good Bacteria' Might Help Fight a Common Gynecologic InfectionMore Evidence Sugary Drinks Harm Women's HeartsAHA News: Prenatal Supplement May Increase Blood Pressure at High DosesMammograms Do Save Women's Lives, Study FindsBreastfeeding May Help Guard Against DiabetesAHA News: How Pregnant Woman's High Blood Pressure Can Change Shape of Baby's HeartMenopause May Someday Disappear as Women Postpone Pregnancy: StudyRural Women at Higher Risk of Early Death From Heart DiseaseEven During Pandemic, Childbirth Safest in Hospital, Doctors' Group SaysDo C-Section Babies Become Heavier Adults?High-Fiber Diets May Lower Odds for Breast CancerWomen in Their 50s Can Lower Their Stroke Risk – Here's HowMental Health Problems After First Baby Reduce Likelihood of More Children: StudyWhen Arteries Narrow, Chest Pain Can Come Earlier for Women Than MenRacial, Ethnic Gaps in Insurance Put Moms, Babies at Risk: StudyStatins Might Reduce Harms From Breast Cancer ChemoExpectant Moms: Take Care and Don't Panic About CoronavirusGene Tests May Guard Older Breast Cancer Patients Against Other TumorsAHA News: Changing the Way We View Women's Heart Attack SymptomsMaria Shriver Sounds the Alarm on Women and Alzheimer'sAHA News: Estrogen Therapy in Early Menopause May Help Keep Arteries ClearDon't Wait, for Your Baby's Sake: Quit Smoking Before You're PregnantFemale Firefighters Face Higher Exposure to CarcinogensNew Moms Need to Watch Out for High Blood PressureBad Sleep, Bad Diet = Bad Heart?A Woman's Guide to Skin Care During and After MenopauseAHA News: What Women Need to Know About Breast Cancer and Heart DiseaseIs High Blood Pressure in First Pregnancy a Harbinger of Heart Trouble?AHA News: Domestic Abuse May Do Long-Term Damage to Women's Health'Couch Potato' Lifestyle Poses Danger to Women's Hearts
Questions and AnswersVideosLinksBook ReviewsSelf-Help Groups
Related Topics

Wellness and Personal Development
Mental Disorders

'Good Bacteria' Might Help Fight a Common Gynecologic Infection

HealthDay News
by By Dennis ThompsonHealthDay Reporter
Updated: May 13th 2020

new article illustration

WEDNESDAY, May 13, 2020 (HealthDay News) -- A dose of healthy bacteria could give women the upper hand in ridding themselves of a common but annoying vaginal infection, a new clinical trial reports.

Women treated with Lactin-V -- an experimental vaginal suppository containing live bacteria -- were much more likely to end their recurring bouts of bacterial vaginosis than women treated with a placebo, the researchers said.

"What we're doing essentially is knocking down the bad bacteria and then replacing the good bacteria, allowing them to grow and keep at bay the bad bacteria as part of an optimal balance," explained lead researcher Dr. Craig Cohen, a professor of obstetrics, gynecology and reproductive sciences at the University of California, San Francisco.

Bacterial vaginosis (BV) is the most common vaginal condition in women aged 15 to 44, affecting nearly 30% of women of reproductive age in the United States, researchers said in background notes.

Every vagina is colonized with different strains of bacteria, Cohen said. Vaginosis occurs when "bad" bacteria overwhelm the normal "good" bacteria.

Symptoms include a thin white or gray vaginal discharge, itching or burning of the vagina, and a strong fishlike odor, according to the U.S. Centers for Disease Control and Prevention.

The condition also increases the risk of premature birth or low birth weight among newborns, as well as upping a woman's risk of contracting HIV and other sexually transmitted diseases, the CDC says.

Standard therapy is to treat the infection with a six-month course of a topical antibiotic gel called metronidazole, said Dr. Taraneh Shirazian, director of global women's health at New York University's School of Global Public Health.

As Cohen and his team sees it, there's a problem with that standard therapy. Once the antibiotic therapy is done, there's nothing to prevent the bad bacteria from overwhelming the vaginal microbiome again.

Because of that, as many as 75% of women have their infection recur within three months of treatment, researchers said.

"They're doing what their provider recommends, they're taking antibiotics, and even though they're doing that, it's coming back," Cohen said.

In the study, 228 women who were diagnosed with bacterial vaginosis were treated with a five-day course of metronidazole gel. Two-thirds of those women were then assigned to receive Lactin-V for 11 weeks.

Lactin-V is a powder that women self-administer with a vaginal applicator. It contains Lactobacillus crispatus, a strain of bacteria that naturally occurs in the vagina. This bacteria produces lactic acid, which inhibits the growth of bad bacteria.

By the end of the initial three months, 30% of women in the Lactin-V group had experienced recurrence of their infection, compared with 45% of women in the placebo group, results showed.

"Essentially, it's associated with a 34% reduced risk of recurrence during that 12-week time period," Cohen said.

The women were tracked out for six months total, and those who received Lactin-V continued to do better, Cohen said.

"We also found approximately 80% of women who were in the Lactin-V arm were successfully colonized with Lactobacillus crispatus, the actual strain we tested," Cohen said.

The findings were published May 14 in the New England Journal of Medicine.

Shirazian said this new treatment looks promising, given that it took three months as opposed to the standard treatment of six months. Currently, women apply antibiotic gel for seven days, then twice weekly for six months to treat recurring bacterial vaginosis.

"That's a lot shorter, which is advantageous," said Shirazian, who wasn't part of the study. "It's hard to continue a therapy for six months. It's hard to maintain it."

However, Shirazian said future trials of Lactin-V would produce stronger results if they compare the new treatment against the current standard therapy as well as placebo.

Researchers are discussing proceeding to stage 3 clinical trials with the maker of Lactin-V, California-based Osel, Inc., Cohen said. There's currently no timeline for getting the new treatment to market.

"I know there are a lot of women suffering from BV, and this product is not available now. It's a long timeline to go through the drug approval process with the [U.S. Food and Drug Administration]," Cohen said.

More information

The U.S. Centers for Disease Control and Prevention have more about bacterial vaginosis.